FMP
Harmony Biosciences Holdings, Inc.
HRMY
NASDAQ
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
32.72 USD
0 (0%)
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-143.28M
-272.13M
-453.6M
-488.19M
Net Income
145.49M
128.85M
181.47M
34.6M
Stock Repurchases
0
-100M
0
0
Dividend Paid
0
0
0
0
Retained Earnings
2.22M
-143.28M
-272.13M
-453.6M
Other Distributions
145.49M
28.85M
181.47M
34.6M
All figures are in USD.
